About
NeuroDerm specializes in integrating proprietary pharmaceutical formulations, state-of-the-art delivery system, and digital health solutions with the aim of reducing disease burden and improving the quality of life of patients and their families.
NeuroDerm’s flagship product ND0612 is currently in late stage development for Parkinson’s disease patients experiencing motor fluctuations. Its system for self-administered continuous subcutaneous infusion of the gold standard levodopa/carbidopa, was designed specifically to be a user-friendly system for people with Parkinson's disease, to maintain steady therapeutic levodopa plasma concentrations for the purpose of improving fluctuations, that is, reducing patients’ "OFF" time without increasing troublesome dyskinesia.
Its tailored solution potentially offers sustained relief (compared to oral immediate-release levodopa/carbidopa treatments) and empowers patients and their families to regain control of their lives with greater daily-life predictability and independence.
Funding history · 2 rounds · $63.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was NeuroDerm founded and where is its headquarters located?
- NeuroDerm was founded in March 2003 and is headquartered in Rehovot, Israel.
- What is NeuroDerm's primary focus in the healthcare sector?
- NeuroDerm specializes in drug-device combination solutions for Central Nervous System Disorders, integrating pharmaceutical formulations, delivery systems, and digital health solutions.
- What is NeuroDerm's flagship product and its purpose?
- NeuroDerm's flagship product is ND0612, a system for self-administered continuous subcutaneous infusion of levodopa/carbidopa, designed for Parkinson's disease patients experiencing motor fluctuations to reduce 'OFF' time.
- When did NeuroDerm complete its Series A funding round and who was an investor?
- NeuroDerm completed its Series A funding round in July 2007, with Robert Taub as an investor.
- When did NeuroDerm conduct its IPO and on which exchange?
- NeuroDerm conducted its IPO in November 2014 on NASDAQ under the ticker NDRM, with a valuation of $164 million.
- When was NeuroDerm acquired and by which company?
- NeuroDerm was acquired in July 2017 by Mitsubishi Tanabe Pharma Corporation for US$1.1 billion in cash.
- What were the results of NeuroDerm's pivotal Phase III BouNDless trial for ND0612?
- In January 2023, NeuroDerm announced highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in Parkinson's disease patients with motor fluctuations.
- What was the total amount of funding raised by NeuroDerm before its acquisition?
- NeuroDerm raised a total of $63.5 million USD before its acquisition.